title: Peripheral blood mononuclear cells inhibit proliferation and promote apoptosis of HeLa cells following stimulation with Bacillus Calmette-Guerin.
abstract: Bacillus Calmette-Guerin (BCG) immunotherapy is established as an effective adjuvant intravesical treatment for non-muscle invasive bladder cancer. BCG is also effective in the treatment of Condylomata acuminata caused by low-risk human papilloma virus (HPV). The aim of this study was to determine the efficacy of BCG for the treatment of cervical cancer or HPV high-risk infections. BCG-activated killer (BAK) cells were incubated with a high-risk HPV18-infected cervical cancer cell line, HeLa. The cell cycle distribution and apoptotic index of the HeLa cells were analyzed by flow cytometry. The alterations of HPV-E7, retinoblastoma (RB) and E2F1 levels were detected at the transcriptional and translational levels. The BAK cell cytotoxicity to HeLa cells was 24.08, 14.74 and 6.8% and the natural killer (NK) cell cytotoxicity was 17.62, 10.78 and 5.8% at the E/T ratios of 40:1, 20:1 and 10:1, respectively. The BAK cells significantly induced the apoptosis of HeLa cells to result in an apoptosis level of 24.2% compared with 13.45% by the NK cell treatment at the ratio of 20:1. BAK cells inhibit the proliferation of HeLa cells by G(1)/S cell cycle arrest and this may be associated with the RB/E2F1 pathway. However, G(1)/S arrest and the alteration of RB protein (pRB) and E2F1 levels in the HeLa cells did not show significant differences between the BAK cell- and NK cell-treated groups. HPV-E7 appeared not to be associated with the alteration in cell cycle progression. This study showed that immunotherapy may be a potential treatment for cervical cancer and that BCG immunotherapy may be an alternative and effective method, but further experiments and clinical trials are required to verify this effect.
authors: Department of Surgical Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003.
authors: Xiaoqing
authors: X
authors: Lu
authors: Lingjiao
authors: L
authors: Wu
authors: Zhuo
authors: Z
authors: Liu
authors: Liping
authors: L
authors: Xie
authors: Shuo
authors: S
authors: Wang
keywords: Bacillus Calmette-Guerin immunotherapy; Bacillus Calmette-Guerin-activated killer cells; HeLa cells; human papilloma virus-E7; peripheral blood mononuclear cells; retinoblastoma/E2F1 pathway
references: Front Biosci. 2008 Jan 01;13:1003-17
references: 17981607
references: J Urol. 2004 Oct;172(4 Pt 1):1490-5
references: 15371877
references: J Urol. 2001 Mar;165(3):834-6
references: 11176481
references: Anticancer Res. 2009 Oct;29(10):4201-4
references: 19846973
references: Cancer Immunol Immunother. 1993 Jul;37(2):105-11
references: 8319241
references: Eur Urol. 2010 May;57(5):774-6; author reply 776-7
references: 20080332
references: Int J Gynaecol Obstet. 2009 Dec;107(3):253-4
references: 19631322
references: World J Urol. 2007 Dec;25(6):563-71
references: 17710407
references: Clin Cancer Res. 2000 Sep;6(9):3729-38
references: 10999767
references: Virus Res. 2002 Nov;89(2):213-28
references: 12445661
references: Cell. 1997 Jul 11;90(1):13-8
references: 9230298
references: Nat Rev Cancer. 2003 Feb;3(2):130-8
references: 12563312
references: Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):788-94
references: 20637913
references: Oncogene. 2005 Apr 18;24(17):2909-15
references: 15838524
references: Development. 2004 Jun;131(11):2737-48
references: 15148303
references: Oncogene. 2005 Apr 18;24(17):2796-809
references: 15838516
references: Cancer Treat Rev. 2010 May;36(3):195-205
references: 20079574
references: Eur Urol. 2001 May;39(5):518-24
references: 11464031
references: Cancer. 2007 Mar 15;109(6):1097-105
references: 17311305
references: Urology. 2005 Feb;65(2):247-50
references: 15708031
references: Int J Cancer. 2001 Jun 1;92(5):697-702
references: 11340575
references: Cancer Res. 2010 Aug 1;70(15):6114-8
references: 20610631